SCHEMBL6173373

SCHEMBL6173373

[CH2]Cc1ccc(-n2cc(-c3ccccc3)nc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.43
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
MAPT P10636 6/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGS2 P35354 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
PTGS1 P23219 1/20 0.39
TP53 P04637 4/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 4/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 3/20 0.38
HSD17B10 Q99714 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175669 0.87 PTGS1 (0.54) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL14007394 0.84 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL4447659 0.83 MAPT (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6178920 0.83 GPR119 (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL4453049 0.82 MAPT (0.40) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL4456197 0.82 MAPT (0.40) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL4453125 0.80 MAPT (0.39) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL4457149 0.79 AGER (0.51) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL15507260 0.77 GPR119 (0.53) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6176741 0.75 GPR119 (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956050-B2 Imidazole compounds as anti-inflammatory and analgesic agents PFIZER, INC. (US) 2005-10-18 US disclosed
EP-1494667-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents HIRANO MISATO (JP) 2003-11-27 US disclosed
WO-2003086390-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, PTGES SMN1; SMN2 4565/4885NPC1 959/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.